Current and investigational treatment of psoriatic arthritis

Bioliography

• BLUMBERG BS, BUNIM JJ, CALKINS E, PIRANI CL, ZVAIFLER NJ: ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritic Rheum. (1964) 7:93–97.
   PubMed Web of Science ®Google Scholar
• BRUCE IN: Psoriatic arthritis: clinical features. In: Rheumatology Hochberg M, Silman A, Smolen J, Weinblatt ME, Weisman M (Eds), Mosby, Philadelphia, USA (2003):1241–1252.
   Google Scholar
• BROCKBANK J, SCHENTAG C, ROSEN C, GLADMAN D: Psoriatic arthritis (PsA) is common among patients with psoriasis and family medical clinic attendees. Arthritis Rheum. (2001) 44:S94.
   Web of Science ®Google Scholar
• MOLL JM, WRIGHT V: Familial occurrence of psoriatic arthritis. Ann. Rheum. Drs. (1973) 32:181–201.
   PubMed Web of Science ®Google Scholar
• BALDING J, KANE D, LIVINGSTONE W et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritic Rheum. (2003) 48:1408–1413.
   PubMed Web of Science ®Google Scholar
• GONZALEZ S, MARTINEZ-BORRA J, LOPEZ-VAZQUEZ A et al.: MICA rather Expert Op/n. lnvestig. Drugs (2004) 13(2)147 than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. Rheumatol. (2002) 29:973–978.
   Google Scholar
• HOHLER T, GROSSMANN S, STRADMANN-BELLINGHAUSEN B et al.: Differential association of polymorphisms in the TNFa region with psoriatic arthritis but not psoriasis. Ann. Rheum. Dis. (2002) 61:213–218.
   PubMed Web of Science ®Google Scholar
• NISHIBU A, OYAMA N, NAKAMURA K et al.: Lack of association of TNF-238A and -308A in Japanese patients with psoriasis vulgaris, psoriatic arthritis and generalized pustular psoriasis. J. Dermatol. Sci. (2002) 29:181.
   PubMed Web of Science ®Google Scholar
• RAHMAN P, BARTLETT S, SIANNIS Fet al.: CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am..). Hum. Genet. (2003) 73:677–681.
   Google Scholar
• BUKHARDT H, HOFFMEYER U, BOHM B et al.: Genetic association of psoriatic arthritis to the candidate gene SLC12A8 on chromosome 3q. Arthritis Rheum. (2003) 48\(Suppl. 9):S406.
   Google Scholar
• GALADARI H, FUCHS B, LEBWOHL M: Newly available treatments for psoriatic arthritis and their impact on skin psoriasis. Int. J. Dermatol. (2003) 42:231–237.
   PubMed Web of Science ®Google Scholar
• HOHLER T, MARKER-HERMANN E: Psoriatic arthritis: clinical aspects, genetics and the role of T cells. Can: Opin. Rheumatol. (2001) 13:273–279.
   PubMed Web of Science ®Google Scholar
• ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumour necrosis factor-a (TNF-a) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. (1994) 96:146–151.
   PubMed Web of Science ®Google Scholar
• TERAJIMA S, HIGAKI M, IGARASHI Y, NOGITA T, KAWASHIMA M: An important role of tumor necrosis factor-a in the induction of adhesion molecules in psoriasis. Arch. Dermatol. Res. (1998) 290:246–252.
   PubMed Web of Science ®Google Scholar
• PARTSCH G, STEINER G, LEEB BF et al.: Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. (1997) 24:518–523.
   PubMed Web of Science ®Google Scholar
• RITCHLIN C, HAAS-SMITH SA, HICKS D et al.: Patterns of cytokine production in psoriatic synovium. Rheumatol. (1998) 25:1544–1552.
   Web of Science ®Google Scholar
• MEASE P: Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin. Exp. Rheumatol. (2002) 20:S116–S121.
   PubMed Web of Science ®Google Scholar
• MOLL JM, WRIGHT V: Psoriatic arthritis. Sernin. Arthritis Rheum. (1973) 3:55–78.
   PubMedGoogle Scholar
• KHAN M, SCHENTAG C, GLADMAN DD: Clinical and radiological changes during psoriatic arthritis disease progression. J. Rheumatol. (2003) 30:1022–1026.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, STAFFORD-BRADY F, CHANG CH, LEWANDOWSKI K, RUSSELL ML: Longitudinal study of clinical and radiological progression in psoriatic arthritis. Rheumatol. (1990) 17:809–812.
   Web of Science ®Google Scholar
• McHUGH NJ, BALACHRISHNAN C, JONES SM: Progression of peripheral joint disease in psoriatic arthritis: a S-yr prospective study. Rheumatology (Oxford) (2003) 42:778–783.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, FAREWELL VT, NADEAU C: Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. Rheumatol. (1995) 22:675–679.
   Web of Science ®Google Scholar
• QUEIRO-SILVA R, TORRE- ALONSO JC, TINTURE-EGUREN T et al.: A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann. Rheum. Dis. (2003) 62:68–70.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, FAREWELL VT, KOPCIUK KA, COOK RJ: HLA markers and progression in psoriatic arthritis. Rheumatol. (1998) 25:730–733.
   Web of Science ®Google Scholar
• JONES G, CROTTY M, BROOKS P: Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br. Rheumatol. (1997) 36:95–99.
   Google Scholar
• GLADMAN DD, HELLIWELL P, MEASE PJ, NASH P, RITCHLIN C, TAYLOR W: Assessment of patients with psoriatic arthritis. A review of currently available measures. Arthritis Rheum. (2004) (In Press).
   Google Scholar
• BLACK RL, O'BRIEN WM, VAN SCOTT EJ et al: Methotrexate therapy in psoriatic arthritis. JAMA (1964) 189:743–747.
   PubMed Web of Science ®Google Scholar
• WILLKENS RF, WILLIAMS HJ, WARD JR et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. (1984) 27:376–381.
   PubMed Web of Science ®Google Scholar
• CUELLAR ML, ESPINOZA LR: Methotrexate use in psoriasis and psoriatic arthritis. Rheum. Dis. Clin. North Am. (1997) 23:797–809.
   PubMed Web of Science ®Google Scholar
• KRAGBALLE K, ZACHARIAE E, ZACHARIAE H: Methotrexate in psoriatic arthritis: a retrospective study. Acta Berm. Venereol. (1983) 63:165–167.
   PubMed Web of Science ®Google Scholar
• ESPINOZA LR, ZAKRAOUI L, ESPINOZA CG et al.: Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J. Rheumatol. (1992) 19:872–877.
   PubMed Web of Science ®Google Scholar
• ABU-SHAKRA M, GLADMAN DD, THORNE JC et al.: Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. Rheumatol. (1995) 22:241–245.
   Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, MEJIAS E et al.:Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1996) 39:2013–2020.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, ABDELLATIF M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. (1999) 42:2325–2329.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, VAM DER LS, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. (1995) 38:618–627.
   PubMed Web of Science ®Google Scholar
• COMBE B, GOUPILLE P, KUNTZ JL et al.: Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. EL.). Rheumatol. (1996) 35:664–668.
   Web of Science ®Google Scholar
• GUPTA AK, GROBER JS, HAMILTON TA et al.: Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.' Rheumatol. (1995) 22:894–898.
   Web of Science ®Google Scholar
• FRASER SM, HOPKINS R, HUNTER JA et al.: Sulphasalazine in the management of psoriatic arthritis. Br. .1. Rheumatol. (1993) 32:923–925.
   Google Scholar
• FARR M, KITAS GD, WATERHOUSE L et al.: Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br. J. Rheumatol. (1990) 29:46–49.
   PubMedGoogle Scholar
• RAHMAN P, GLADMAN DD, COOK RJ, ZHOU Y, YOUNG G: The use of sulfasalazine in psoriatic arthritis: a clinic experience. Rheumatol. (1998) 25:1957–1961.
   Web of Science ®Google Scholar
• GUPTA AK, MATTESON EL, ELLIS CNet al.: Cyclosporine in the treatment of psoriatic arthritis. Arch. Dermatol. (1989) 125:507–510.
   Google Scholar
• SALVARANI C, MACCHIONI P, BOIARDI L et al.: Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. Rheumatal. (1992) 19:74–79.
   PubMed Web of Science ®Google Scholar
• STEINSSON K, JONSDOTTIR I, VALDIMARSSON H: Cyclosporin A in psoriatic arthritis: an open study. Ann. Rheum. Dis. (1990) 49:603–606.
   PubMed Web of Science ®Google Scholar
• SARZI-PUTTINI P, CAZZOLA M, PANNI B et al.: Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatal. hat. (2002) 21:234–238.
   PubMed Web of Science ®Google Scholar
• DOYLE DV, HUSKISSON EC, GREENWOOD A, DACRE JE: Psoriatic arthritis (PsA) - a placebo controlled study of treatment with cyclosporin A (CyA) and azathioprine (Aza). Br. Rheumatal. (1989) 28\(Suppl. 1):53.
   Google Scholar
• SPADARO A, RICCIERI V, SILI SCAVALLI A et al: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin. Exp. Rheumatal. (1995) 13:589–593.
   PubMed Web of Science ®Google Scholar
• SALVARANI C, MACCHIONI P, OLIVIERI I et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. Rheumatal. (2001) 28:2274–2282.
   PubMed Web of Science ®Google Scholar
• MACCHIONI P, BOIARDI L, CREMONESI T et al.: The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatal. Int. (1998) 18:27–33.
   PubMed Web of Science ®Google Scholar
• DORWART BB, GALL EP, SCHUMACHER HR, KRAUSER RE: Chrysotherapy in psoriatic arthritis. Efficacy and toxicity compared to rheumatoid arthritis. Arthritic Rheum. (1978) 21:513–515.
   PubMed Web of Science ®Google Scholar
• RICHTER MB, KINSELLA P, CORBETT M: Gold in psoriatic arthopathy. Ann. Rheum. Dis. (1980) 39:279–280.
   PubMed Web of Science ®Google Scholar
• DEQUEKER J, VERDICKT W, GEVERS G, VANSCHOUBROEK K: Longterm experience with oral gold in rheumatoid arthritis and psoriatic arthritis. Clin. Rheumatal. (1984) 3:67–74.
   PubMed Web of Science ®Google Scholar
• TUMIATI B, BARICCHI R, BELLELLI A: Psoriatic arthritis. Long term treatment with auranofin. Clin. Rheumatal. (1986) 5:124–125.
   PubMed Web of Science ®Google Scholar
• CARETTE S, CALIN A, McCAFFERTY JP, WALLIN BA: A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritic Rheum. (1989) 32:158–165.
   PubMed Web of Science ®Google Scholar
• PALIT J, HILL J, CAPELL HA et al: A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br. .1. Rheumatal. (1990) 29:280–283.
   PubMedGoogle Scholar
• LACAILLE D, STEIN HB, RABOUD J, KLINKHOFF AV: Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? .1. Rheumatal. (2000) 27:1922–1927.
   PubMed Web of Science ®Google Scholar
• MADER R, GLADMAN DD, LONG J, GOUGH J, FAREWELL VT: Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin. Invest. Med. (1995) 18:139–143.
   Web of Science ®Google Scholar
• MAZZANTI G, COLONI L, DE SABBATA G, PALADINI G: Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Berm. Venereal Sapp]. (Stockh (1994) (Suppl. 186):116–117.
   Google Scholar
• CLARK CM, KIRBY B, MORRIS AD et al.: Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br. Dermatal. (1999) 141:279–282.
   PubMed Web of Science ®Google Scholar
• FRASER AD, VAN KARYK A, WESTHOVEN R et al.: A randomized double-blind, placebo controlled multi-centre trial of combination therapy with methotrexate plus cyclosporin versus methotrexate plus placebo in patients with active psoriatic arthritis (PsA). Arthritic Rheum. (2003) 48\(Suppl. 9):S170.
   Google Scholar
• FREDRICKSSON T, PETERSSON U: Severe psoriasis: oral therapy with a new retinoid. Dermatologica (1978) 157:238–244.
   PubMedGoogle Scholar
• SCOTT DL, SMOLEN JS, KALDEN JR et al.: Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann. Rheum. Dis. (2001) 60:913–923.
   PubMed Web of Science ®Google Scholar
• SCARPA R, MANGUSO F, ORIENTE A, PELUSO R, ORIENTE, P: Leflunomide in psoriatic polyarthritis: an Italian pilot study. Arthritis Rheum. (2001) 44:S92.
   Web of Science ®Google Scholar
• LIANG G, BARR W: Long term follow-up of the use of leflunomide (LF) in recalcitrant psoriatic arthritis (PA) and psoriasis (PS). Arthritis Rheum. (2001) 44:S121.
   Web of Science ®Google Scholar
• KALTWASSER P, NASH P, GLADMAN D, MEASE P: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis: results from the TOPAS study. Arthritic Rheum. (2002) 46:3416–3417.
   Web of Science ®Google Scholar
• MEASE PJ: Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis. (2002) 61:298–304.
   PubMed Web of Science ®Google Scholar
• KRAAN MC, VAN KUIJK AW, DINANT HJ et al: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. (2002) 46:2776–2784.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ J et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
   PubMed Web of Science ®Google Scholar
• MEASE P, KIVITZ A, BURCH F, SIEGEL E, COHEN S, BURGE D: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a Phase III multi-centre clinical trial. Arthritic Rheum. (2001) 44:S90.
   Web of Science ®Google Scholar
• ORY P, SHARP J, SALONEN D et al.: Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis. Arthritis Rheum. (2002) 46:S196.
   Web of Science ®Google Scholar
• RITCHLIN CT, HAAS-AMITH SA, SHAO T et al.: Etanercept lowers the frequency of circulating osteoclast precursors (OCP) and improves bone marrow edema in patients with erosive psoriatic arthritis. Arthritic Rheum. (2003) 48:3660.
   Web of Science ®Google Scholar
• MARZO-ORTEGA H, McGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal 149 Expert Op/n. lnvestig. Drugs (2004) 13(2) pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. (2001) 44:2112–2117.
   Google Scholar
• ANTONI C, DECHANT C, LORENZ H et al.: Successful treatment of severe psoriatic arthritis with infliximab. Arthritis Rheum. (1999) 42:S371.
   Web of Science ®Google Scholar
• ANTONI C, DECHANT C, OGILVIE A, KALDEN-NEMETH D, KALDEN JR, MANGER B: Successful treatment of psoriatic arthritis with infliximab in a MRI controlled study.' Rheumatol (2000) 27:24.
   Google Scholar
• CHAUDHARI U, ROMANO P, MULCAHY LD, DOOLEY LT, BAKER DG, GOTTLIEB AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 357:1842–1847.
   PubMed Web of Science ®Google Scholar
• ANTONI C, KAVANAUGH A, KIRKHAM B et al.: The infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. (2002) 46:S381.
   Web of Science ®Google Scholar
• ANTONI C, KAVANAUGH A, KIRKHAM B et al.: The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. (2003) 48:S265.
   Web of Science ®Google Scholar
• PROVENZANO G, TERMINI A, LE MOLT C, RINALDI F: Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. Ann. Rheum. Dis. (2003) 62:680–681.
   PubMed Web of Science ®Google Scholar
• SALVARANI C, CANTINI F, OLIVIERI I et al.: Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. (2003) 49:541–545.
   PubMed Web of Science ®Google Scholar
• CAUZA E, SPAK M, CAUZA K et al.: Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol. Int. (2002) 22:227–232.
   PubMed Web of Science ®Google Scholar
• FELETAR M, BROCKBANK JB, SCHENTAG C, LAPP V, GLADMAN DD: Treatment of refractory psoriatic arthritis with Infliximab - a 12 month observational study of 16 patients. Ann. Rheum. Dis. (2004) 63:156–161.
   PubMed Web of Science ®Google Scholar
• TAK PP, KRAAN MC, GOEDKOOP AY et al.: Early effects of infliximab therapy on inflammatory cells in lesional epidermis and synovial tissue of patients with psoriatic arthritis. Arthritis Rheum. (2003) 48 (Suppl. 9):S168.
   Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48:35–45.
   PubMed Web of Science ®Google Scholar
• KRUEGER G, CALLIS K: Aldarept to treat psoriasis. In: Therapy of Moderate-to-Severe Psoriasis. Weinstein G, Gottlieb A (Eds), Marcel Dekker, Inc., New York (2003):287–306.
   Google Scholar
• ELLIS CN, KRUEGER GG, ALEFACEPT CLINICAL STUDY GROUP: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. I Med. (2001) 345:248–255.
   PubMed Web of Science ®Google Scholar
• KRUEGER GG, PAPP KA, STOUGH DB et al.: A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. Am. Acad. Dermatol (2002) 47:821–833.
   PubMed Web of Science ®Google Scholar
• LOWE NJ, GONZALEZ J, BAGEL J et al.: Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int. Dermatol (2003) 42:224–230.
   PubMed Web of Science ®Google Scholar
• LEONARDI CL: Treament of psoriasis using efalizumab. In: Therapy of Moderate-to-Severe Psoriasis. Weinstein G, Gottlieb A (Eds), Marcel Dekker, Inc., New York (2003):333–350.
   Google Scholar
• UTSET TO, AUGER JA, PEACE D et al.: Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. Rheumatol (2002) 29: 1907-1913.
   Google Scholar
• UTSET TO, AUGER JA, PEACE D et al.: Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. Arthritis Rheum. (2001) 44:S92. Web sites
   Google Scholar
• http://www.docguide.com/news/ content.nsfinews/ IPS: Onercept (rhTBP-1) Promising Treatment For Psoriasis, Psoriatic Arthritis. Affiliation
   Google Scholar